IMS Health — Q3 2014 Earnings Presentation
20 slides from IMS Health's earnings presentation, Oct 24, 2014
Slide 1: IMS Health Q3 2014 Earnings Call
IMS Health Q3 2014 Earnings Call October 24, 2014 IMS Health Confidential. (c) 2014 IMS Health Incorporated. All Rights Reserved.
Slide 2: Legal
Legal This presentation should be viewed in conjunction with IMS Health’s Q3 2014 earnings call Safe Harbor Statement This presentation includes “forward-looking statements”, including statements regarding future financial and operating results, especially those set forth under the heading “Full-Yea
Slide 3: 3rd Quarter Results
3rd Quarter Results $M Revenue EBITDA +5.4% +10.5% @ CFx @ CFx $656 $633 $221 $209 Q3 2013 Q3 2014 Q3 2013 Q3 2014 Dollars are actual foreign exchange rates. CFx is constant currency. EBITDA is “Adjusted EBITDA” as defined in the IMS Health earnings release IMS Health Confidential. Do not distribute
Slide 4: Cegedim Update
Cegedim Update Works council information and consultation requirements Cegedim Board of Directors approval Fully executed Definitive Purchase Agreement Regulatory review and other customary closing conditions Close expected in early Q2 2015 IMS Health Confidential. Do not distribute outside yo
Slide 5: 3rd Quarter Offering Revenue
3rd Quarter Offering Revenue Offering 3rdd Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Information $382 $381 1.8% 0.0% Technology $274 $252 10.8% 9.3% Services Total $656 $633 5.4% 3.7% IMS Health Confidential. Do not distribute outside your organization. 5 (c) 2014 IMS Health
Slide 6: 3rd Quarter Geographic Revenue
3rd Quarter Geographic Revenue Geography 3rd Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Emerging Markets $115 $110 10.4% 4.6% Developed Markets $541 $523 4.3% 3.5% Total $656 $633 5.4% 3.7% IMS Health Confidential. Do not distribute outside your organization. 6 (c) 2014 IMS He
Slide 7: 3rd Quarter EBITDA
3rd Quarter EBITDA 3rd Quarter Versus Prior Year Constant $M 2014 2013 Reported Currency Adjusted EBITDA $221 $209 10.5% 6.1% Adjusted EBITDA 33.7% 32.9% 159 bps 76 bps margin g IMS Health Confidential. Do not distribute outside your organization. 7 (c) 2014 IMS Health Incorporated. All Rights Reser
Slide 8: 3rd Quarter P&L
3rd Quarter P&L $M (except per share data) 2014 2013 Net Income / (Loss) $47 $(20) Adjusted Net Income $125 $134 Diluted Earnings / (Loss) per Share $0.14 $(0.07) Adjusted Diluted Earnings per Share $0.37 $0.47 IMS Health Confidential. Do not distribute outside your organization. 8 (c) 2014 IMS Heal
Slide 9: Year-to-date Revenue
Year-to-date Revenue Offering Year-to-date Versus Prior Year Constant $M $ 2014 2013 Reported p C Currency Information $1,149 $1,138 1.9% 0.9% Technology $814 $732 11.7% 11.3% S Services i Total $1,963 $1,870 5.8% 5.0% Geography Year-to-date Versus Prior Year Emerging Markets $346 $323 11.2% 7.4% De
Slide 10: Year-to-date P&L
Year-to-date P&L $M (except per share data) 2014 2013 Adjusted EBITDA $664 $618 Adjusted EBITDA margin 33.8% 33.0% Net Income / (Loss) $(197) $0 Adjusted Net Income $329 $306 Diluted Earnings / (Loss) per Share $(0.63) $0.00 Adj t d Dil Adjusted Diluted t d Earnings E i per Share Sh $1 02 $1.02 $1 0
Slide 11: 3rd Quarter Balance Sheet Items & Metrics
3rd Quarter Balance Sheet Items & Metrics $M 2014 2013 Cash & Cash Equivalents & Short Term $355 $729 (1) I Investments t t (3) Principal Balance of Debt (2) $3,923 $5,027 (1) Net Debt $3,568 $4,298 (1) Gross Leverage Ratio 4.5x 6.1x (1) Cash Provided by Operating Activities $191 $212 Capital Expend
Slide 12: Full-Year 2014 Guidance
Full-Year 2014 Guidance Constant Currency Reported (1) Revenue Growth 5 5 – 5.7% 5.5 5 7% 3 8 – 4.0% 3.8 4 0% Adjusted EBITDA Growth 9.0 – 9.8% 5.8 – 6.6% Adjusted Net Income Growth 20 – 21% 15 – 16% Adjusted Diluted EPS 1.40 – 1.42 1.34 – 1.36 Unlevered FCF/Adj. EBITDA (2) N/A 70 – 75% (1) Assuming
Slide 13: Foreign Currency Impact
Foreign Currency Impact 2014 - Reported vs. constant currency (reported < constant currency), reported > constant currency Growth rate impact of FX Q1 Q2 Q3 Q4 (1) FY (1) Revenue (1.4)% 0.7% (1.7)% (4.3)% (1.7)% EBITDA (2.3)% (0.1)% (4.4)% (5.7)% (3.2)% (1) Assuming FX rates remain unchanged from Se
Slide 14: Q&A
Q&A IMS Health Confidential. (c) 2014 IMS Health Incorporated. All Rights Reserved.
Slide 15: Appendix: Non-GAAP Financial Measures
Appendix: Non-GAAP Financial Measures IMS Health Confidential. (c) 2014 IMS Health Incorporated. All Rights Reserved.
Slide 16: Net Income to Adjusted EBITDA
Net Income to Adjusted EBITDA Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2014 2013 2014 2013 Net Income (Loss) $ 47 $ (20) $ (197) $ — Provision for (benefit from) income taxes 11 (20) (141) (6) Other (income) loss, net(1) (7) 54 281 44 Interest expense 43 87 181
Slide 17: Net Income to Adjusted Net Income & Per Share Data
Net Income to Adjusted Net Income & Per Share Data Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share data) 2014 2013 2014 2013 Net Income (Loss) $ 47 $ (20) $ (197) $ — Provision for (benefit from) income taxes 11 (20) (141) (6) Amortization associated w
Slide 18: Unlevered Free Cash Flow
Unlevered Free Cash Flow Three Months Ended Nine Months Ended September 30, September 30, (in millions) 2014 2013 2014 2013 Net Cash (Used in) Provided by Operating Activities $ 191 $ 212 $ (37) $ 336 Capital expenditures (14) (8) (59) (25) Additions to computer software (26) (22) (70) (53) Free Cas
Slide 19: Gross Leverage Ratio
Gross Leverage Ratio (in millions) Gross Debt as of September 30, 2014 $ 3,923 Adjusted EBITDA for the year ended December 31, 2013 829 Less: Adjusted EBITDA for the nine months ended September 30, 2013 (618) Add: Adjusted EBITDA for the nine months ended September 30, 2014 664 Adjusted EBITDA for t
Slide 20: END
END IMS Health Confidential. Do not distribute outside your organization. 20 (c) 2014 IMS Health Incorporated. All Rights Reserved.